References with PepMix™ Peptide Pools - Tumor Associated Antigens

2025

2024

Molecular mimicry in multisystem inflammatory syndrome in children
Bodansky et al., Nature (2024) - PMID: 39112696
Product used: custom PepMix (SXN8)
Autoantigen-specific CD4+ T cells acquire an exhausted phenotype and persist in human antigenspecific autoimmune diseases
Saggau et al., Immunity (2024) - PMID: 39226901
Product used: PepMix™ Human (MOG)
Immunogenicity and safety of an Entamoeba histolytica adjuvanted protein vaccinecandidate (LecA+GLA-3M-052 liposomes) in rhesus macaques
Abhyankar et al., Human Vaccines & Immunotherapeutics (2024) - PMID 39090779
Product used: custom PepMix
Vaccination with Tozimameran Induces T-Cell Activation, but Not Senescent or Exhaustive Alterations, in Kidney Transplant Recipients
Stai et al,. Vaccines (2024)
Product used: custom PepMix
Circulating tumor-associated antigen-specific IFN? + 4-1BB + CD8 + T cells as peripheral biomarkers of treatment outcomes in patients with pancreatic cancer
Murakami et al., Frontiers in Immunology (2024)
Products used: PepMix Human (CEA), Human (TERT), Human (WT1/WT33), Human (Mucin-1)
Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in resectable esophageal/gastroesophageal junction cancer: a phase Ib trial and ctDNA analyses
Kelly et al., Nature Medicine (2024)
Multimodal single-cell profiling of T lymphocytes in infection and cancer
Bieberich, Dissertation (2024)
Products used: PepMix Human (CEA), Human (MAGEA3), Human (NY-ESO-2), Human (WT1/WT33)
Vaccines targeting ESR1 activating mutations elicit anti-tumor immune responses and suppress estrogen signaling in therapy resistant ER+ breast cancer
Dailey et al., Human Vaccines & Immunotherapeutics (2024) - PMID: 38330990
Products used: Custom PepMix (ESR1), PepMix HIV-1 (GAG) Ultra

Archive

Prophylactic Vaccination and Intratumoral Boost with HER2-Expressing Oncolytic Herpes Simplex Virus Induces Robust and Persistent Immune Response against HER2-Positive Tumor Cells
Delwar et al., Vaccines (2023)
Product used: PepMix Human (ErbB2_ECD)
Neoantigen-specific CD4+ tumor-infiltrating lymphocytes are potent effectors identified within adoptive cell therapy products for metastatic melanoma patients
Hall et al., Journal for Immunotherapy of Cancer (2023) - PMID: 37802604
Product used: Custom PepMix
Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer
Rojas et al., Nature (2023) - PMID: 37165196
Product used: Custom PepMix

Pre-existing immunity does not impair the engraftment of CRISPR-Cas9-edited cells in rhesus macaques conditioned with busulfan or radiation

S. pyogenes (CAS9)_2 subpools

Study of genes involved in HER2-positive breast cancer progression for identification of new therapeutic targets
Ruzzi, Dissertation (2023)
Product used: custom PepMix (HER2)
Untersuchungen zur Kreuzreaktivität von Cytomegalievirusspezifischen T-Lymphozyten und Tumorassoziierten Antigenen
Weiß, Dissertation (2023)
Products used: PepMix™ CMVA (pp65), Human (Mucin-1), Human (NY-ESO-1), Human (Prame/OIP4) & Human (WT1/WT33)
Non-Mutated Nucleophosmin 1 Is Recognized by the CD8+ T Lymphocytes of an AML Patient after the Transplantation of Hematopoietic Stem Cells from an HLA-Haploidentical Donor
Nemeckova et al., Current Oncology (2023) - PMID: 35621629
Products used: PepMix Human (Prame/OIP4), Human (Mucin-1)
Identification of shared tumor epitopes from endogenous retroviruses inducing high-avidity cytotoxic T cells for cancer immunotherapy
Bonaventura et al., Immunology (2022)
Exploiting the DNA Damaging Activity of Liposomal Low Dose Cytarabine for Cancer Immunotherapy
Lewicky et al., Pharmaceutics (2022)
Products used: PepMix Human (Mucin-1),Human (TERT), Human (CEA)
Interdependence of sequential CTL and NK cellcytotoxicityagainst melanomacells
Friedmann et al., Journal of Physiology (2022)
Product used: PepMix Human (Melan-A/MART-1)
Prevention and Therapy of Metastatic HER-2+ Mammary Carcinoma with a Human Candidate HER-2 Virus-like Particle Vaccine
Ruzzi et al., Biomedicines (2022)
A phase I study of an adenoviral vector delivering a MUC1/CD40-ligand fusion protein in patients with advanced adenocarcinoma
Tan et al., Nature Communications (2022)
Product used: PepMix Human (Mucin-1)
CD39+ tissue-resident memory CD8+ T cells with a clonal overlap across compartments mediate antitumor immunity in breast cancer
Lee et al., Science Immunology (2022) - PMID: 36026440
Product used: PepMix Human (NY-ESO-1)
Local delivery of low-dose anti–CTLA-4 to the melanoma lymphatic basin leads to systemic Tregreduction and effector T cell activation
van Pul et al., Science Immunology
Products used: PepMix Human NY-ESO-1, Human Melan-A/MART1, CEFT Pool
Multi-antigen-targeted T-cell therapy to treat patients with relapsed/refractory breast cancer
Hoyos et al., Therapeutic Advances in Medical Oncology (2022)
Products used: PepMix Human Survivin, Human NY-ESO-1, Human PRAME/OIP4, Human MAGEA4, Human SSX2
An Autologous Dendritic Cell Vaccine Promotes Anticancer Immunity in Patients with Ovarian Cancer with Low Mutational Burden and Cold Tumors
Fucikova et al., Clinical Cancer Research (2022) - PMID: 35536547
Products used: PepMix Human (MAGAE3), Human ( MUC1)
Non-Mutated Nucleophosmin 1 Is Recognized by the CD8+ T Lymphocytes of an AML Patient after the Transplantation of Hematopoietic Stem Cells from an HLA-Haploidentical Donor
Nemeckova et al., Current Oncology (2022)
Identification of Claudin 6-specific HLA class I- and HLA class II-restricted T cell receptors for cellular immunotherapy in ovarian cancer
Matsuzaki et al., Oncoimmunology (2022) - PMID: 35003898
Products used: PepMix™ Human (Claudin-6)
The human CXCR3 chemokine system in early differentiated CD8+ T cell function and solid tumors
Tino Vollmer, Dissertation (2022)

Videos of Sipuleucel-T Programmed T Cells Lysing Cells That Express Prostate Cancer Target Antigens
Adam S Kibel et al., J Natl Cancer Inst. (2021) - PMID: 33630063
Products used: PM-PSA
Phenotype, Specificity and Avidity of Antitumour CD8+ T Cells in Melanoma
Giacomo Oliveira et al., Nature, (2021)
Targeting Human Acyl-CoA:Cholesterol Acyltransferase as a Dual Viral and T Cell Metabolic Checkpoint
Nathalie M. Schmidt et al., Nature Communications, (2021)
Products used: PM-NYE, PM-MAGEA1, PM-AFP
Design of Peptides With High Affinity Binding to a Monoclonal Antibody as a Basis For Immunotherapy
Surendra S. Negi et al., Peptides, (2021)
Early disappearance of tumor antigenreactive T cells from peripheral blood correlates with superior clinical outcomes in melanoma under antiPD-1 therapy
Jonas Bochem et al., Journal Immunology, (2021)
Products used: PM-MelA, PM-NYE
Functional T Cell Reactivity to Melanocyte Antigens Is Lost during the Progression of Malignant Melanoma, but Is Restored by Immunization
Anna Przybyla et al., Cancers (Basel) (2021) - PMID: 33435427
Products used: PM-GP100, PM-NYE, PM-Tyr, PM-MAGEA3, PM-MelA
Identification of Novel HLA-Restricted Preferentially Expressed Antigen in Melanoma Peptides to Facilitate Off-The-Shelf Tumor-Associated Antigen-Specific T-Cell Therapies
Maja Stanojevic et al., Cytotherapy, (2021)
Products used: PM-OIP4, PM-ACTS
Activation of Resident Memory T Cells For Cancer Immunotherapy
David B. Masopust Jr. et.al., United States Patent Application 20210000935 (2021) - PMID: n.a.

Clinical Effects of Administering Leukemia-Specific Donor T Cells to Patients With AML/MDS Post-Allogeneic Transplant
Premal Lulla et al., Blood (2020) - PMID: 33270816
Products used: PM-Survivin, PM-WT1, PM-OIP4, PM-NYE
Oncolytic Measles Virus Therapy Enhances Tumor Antigen-Specific T-Cell Responses in Patients With Multiple Myeloma
Nandakumar Packiriswamy et al., Leukemia (2020) - PMID: 32327728
Products used: PM-MAGEA1, PM-MAGEA3, PM-MAGEC1, PM-WT1, PM-OIP4, PM-SSX2, PM-TERT, PM-p53, PM-MUC-1, PM-NYE
Pre-Transplant Assessment of pp65-Specific CD4 T Cell Responses Identifies CMV-Seropositive Patients Treated With rATG at Risk of Late Onset Infection
Maria O. López-Oliva et al., Clinical Immunology (2020) - PMID: 31891764
Products used: PM-IE1, PM-PP65-1
Targeting Antigen to the Surface of EVs Improves the In Vivo Immunogenicity of Human and Non-human Adenoviral Vaccines in Mice
Carly M. Bliss et al., Molecular Therapy: Methods & Clinical Development (2019) - PMID: 31934599
Evaluation of Newcastle Disease Virus Mediated Dendritic Cell Activation and Cross‐Priming Tumor‐Specific Immune Responses Ex Vivo
Qi Xu et al., International Journal of Cancer (2019) - PMID: 31584185
Natural T Cell Autoreactivity to Melanoma Antigens: Clonally Expanded Melanoma-Antigen Specific CD8 + Memory T Cells Can be Detected in Healthy Humans
Anna Przybyla et al., Cancer Immunology, Immunotherapy (2019) - PMID: 30783693
The Human CD4 T Cell Response Against Mumps Virus Targets a Broadly Recognized Nucleoprotein Epitope
Jelle de Wit et al., Journal of Virology (2019) - PMID: 30626672
Vaccine-Induced Memory CD8+ T Cells Provide Clinical Benefit in HER2 Expressing Breast Cancer: a Mouse to Human Translational Study
Erika J Crosby et al., Clinical Cancer Research (2019) - PMID: 30635338
Tel-eVax: a Genetic Vaccine Targeting Telomerase for Treatment of Canine Lymphoma
Joseph A. Impellizeri et al., Journal of Translational Medicine (2018) - PMID: 30537967
Over-Expression of PD-1 Does Not Predict Leukemic Relapse After Allogeneic Stem Cell Transplantation
Jain et al., Biology of Blood and Marrow Transplantation (2018) - PMID: n.a.
A Novel Allogeneic Off-The-Shelf Dendritic Cell Vaccine for Post-Remission Treatment of Elderly Patients with Acute Myeloid Leukemia
Loosdrecht et al., Cancer Immunol Immunother. (2018) - PMID: 30039426
PRAME Peptide‐Specific CD8+ T Cells Represent the Predominant Response Against Leukemia‐Associated Antigens (LAAs) in Healthy Individuals
Matko et al., European Journal of Immunology (2018) - PMID: 29738081
Combined IFN-γ and TNF-α Release Assay for Differentiating Active Tuberculosis from Latent Tuberculosis Infection
Kim et al., Journal of Infection (2018) - PMID: 29746954
Personalized ex vivo Multiple Peptide Enrichment and Detection of T Cells Reactive to Multiple Tumor-associated Antigens in Prostate Cancer Patients
Taborska et al., Med Oncol. (2017) - PMID: 28866803
An Immunogenic Personal Neoantigen Vaccine for Patients with Melanoma
Ott et al., Nature (2017) - PMID: 28678778
Personalized RNA Mutanome Vaccines Mobilize Poly-specific Therapeutic Immunity Against Cancer
Sahin et al., Nature (2017) - PMID: 28678784
Spontaneous CD4+ and CD8+ T Cell Responses Directed Against Cancer Testis Antigens are Present in the Peripheral Blood of Testicular Cancer Patients
Pearce et al., European Journal of Immunology (2017) - PMID: 28555838
Generation of T Cell Effectors Using Tumor Cell-Loaded Dendritic Cells for Adoptive T Cell Therapy
Vavrova et al., Medical Oncology (2016) - PMID: 27812850
A Phase I Study of Recombinant (r) Vaccinia-CEA (6D)-TRICOM and rFowlpox-CEA (6D)-TRICOM Vaccines with GM-CSF and IFN-α-2b in Patients with CEA-Expressing Carcinomas
Duggan et al., Cancer Immunology, Immunotherapy (2016) - PMID: 27581603
Prognostic Impact of High Levels of Circulating Plasmacytoid Dendritic Cells in Breast Cancer
Bailur et al., Journal of Translational Medicine (2016) - PMID: 27234566
Dysfunction of PSA-Specific CD8+ T Cells in Prostate Cancer Patients Correlates with CD38 and Tim-3 Expression
Japp et al., Cancer Immunol Immunother. (2015) - PMID: 26289091
An HPV-E6/E7 Immunotherapy Plus PD-1 Checkpoint Inhibition Results in Tumor Regression and Reduction in PD-L1 Expression
Rice et al., Cancer Gene Therapy (2015) - PMID: 26337747
Survivin-Specific CD4+ T Cells are Decreased in Patients with Survivin-Positive Myeloma
Locke et al., J Immunother Cancer (2015) - PMID: 25992291
A Phase I Trial Combining Decitabine/dendritic Cell Vaccine Targeting MAGE-A1, MAGE-A3 and NY-ESO-1 for Children with Relapsed or Therapy-Refractory Neuroblastoma and Sarcoma
Krishnadas et al., Cancer Immunol Immunother. (2015) - PMID: 26105625
Guidelines For the Automated Evaluation of Elispot Assays
Janetzki et al., Nature Protocols (2015) - PMID: 26110715
Functional Immunological Parameters Associated with Long-term Survival of Patients with Metastatic Melanoma
Henning Zelba, Dissertation der Mathematisch-Naturwissenschaftlichen Fakultät der Eberhard Karls Universität Tübingen (2015) - PMID: n.a
Presence of Circulating Her-2-reactive CD8 + T-Cells is Associated with Lower Frequencies of Myeloid-derived Suppressor Cells and Regulatory T Cells, and Better Survival in Elderly Breast Cancer Patients
Kini Bailur et al., Breast Cancer Research (2015) - PMID: n.a.
STAT3 Signaling Contributes to the High Effector Activities of Interleukin-15-derived Dendritic Cells
Okada et al., Immunol Cell Biol. (2015) - PMID: 25582338
Myeloid-Derived Suppressor Cells Predict Survival of Patients with Advanced Melanoma: Comparison with Regulatory T Cells and NY-ESO-1- or Melan-A-Specific T Cells
Weide et al., Clin Cancer Res. (2014) - PMID: 24323899
Vaccines Against Antigens Involved in Therapy Resistance and Methods of Using Same
Lyerly et al., US Patent 20,140,377,261 (2014) - PMID: n.a.
Establishment and Maintenance of a PBMC Repository for Functional Cellular Studies in Support of Clinical Vaccine Trials
Sambor et al., J Immunol Methods. (2014) - PMID: 24787274
A Recombinant Modified Vaccinia Ankara Vaccine Encoding Epstein-Barr virus (EBV) Target Antigens: a Phase I Trial in UK Patients with EBV-positive Cancer
Taylor et al., Clinical Cancer Research (2014) - PMID: 25124688
Circulating CD4+ T Cells That Produce IL4 or IL17 When Stimulated by Melan-A but Not by NY-ESO-1 Have Negative Impacts on Survival of Patients with Stage IV Melanoma
Zelba et al., Clin. Cancer Res. (2014) - PMID: 24938524
Common Ewing Sarcoma-Associated Antigens Fail to Induce Natural T Cell Responses in Both Patients and Healthy Individuals
Altvater et al., Cancer Immunol Immunother. (2014) - PMID: 24973179
Intralesional Treatment of Stage III Metastatic Melanoma Patients with L19–IL2 Results in Sustained Clinical and Systemic Immunologic Responses
Weide et al., Cancer Immunology. (2014) - PMID: 24906352
Vaccination with Autologous Dendritic Cells Loaded with Autologous Tumor Lysate or Homogenate Combined with Immunomodulating Radiotherapy and/or Preleukapheresis IFN-α in Patients with Metastatic Melanoma: a Randomised “Proof-of principle” Phase II Study
de Rosa et al., J Transl Med. (2014) - PMID: 25053129
Normalizing ELISPOT Responses to T-cell Counts: a Novel Approach for Quantification of HCMV-Specific CD4+ and CD8+ T-Cell Responses in Kidney Transplant Recipients
Calarota et al., Journal of Clinical Virology (2014) - PMID: n.a.
Combination of Interleukin-12 gene Therapy, Metronomic Cyclophosphamide and DNA Cancer Vaccination Directs all Arms of the Immune System Towards Tumor Eradication
Denies et al., Journal of Controlled Release (2014) - PMID:24887014
Decitabine Facilitates Immune Recognition of Sarcoma Cells by Upregulating CT Antigens, MHC molecules, and ICAM-1
Krishnadas et al., Tumour Biol. (2014) - PMID: 24584817
T-Cell Responses after Haematopoietic Stem Cell Transplantation for Aggressive Relapsing-Remitting Multiple Sclerosis
Burman et al., Immunology (2013) - PMID: 23721329
Lentivirus-Induced Dendritic Cells for Immunization Against High-Risk WT1+ Acute Myeloid Leukemia
Sundarasetty et al., Hum Gene Ther. (2013) - PMID: 23311414
Generation of Multi-Leukemia Antigen-Specific T Cells to Enhance the Graft-Versus-Leukemia Effect After Allogeneic Stem Cell Transplant
Weber et al., Natur Leukemia (2013) - PMID: 23528871
Generation of Tumor Antigen-Specific T Cell Lines from Pediatric Patients with Acute Lymphoblastic Leukemia—Implications for Immunotherapy
Weber et al., Clin. Cancer Res. (2013) - PMID: 23838315
Induction of Tumoricidal Function in CD4+ T Cells is Associated with Concomitant Memory and Terminally Differentiated Phenotype
Hirschhorn-Cymerman et al., J. Exp. Med. (2012) - PMID: 23008334
Three Sensitive Assays Do Not Provide Evidence for Circulating HuD-specific T cells in The Blood of Patients with Paraneoplastic Neurological Syndromes with Anti-Hu Antibodies
de Jonste et al., Neuro Oncology. (2012) - PMID: 22591661
Functional T Cells Targeting NY-ESO-1 or Melan-A Are Predictive for Survival of Patients With Distant Melanoma Metastasis
Weide et al., J. Clin. Oncol. (2012) - PMID: 22529253
Cytotoxic T Lymphocytes Simultaneously Targeting Multiple Tumor-associated Antigens to Treat EBV Negative Lymphoma
Gerdemann et al., Molecular Therapy (2011) - PMID: 21915103
Improving T-Cell Therapy for Relapsed EBV-Negative Hodgkin Lymphoma by Targeting Upregulated MAGE-A4
Cruz et al., Clin. Cancer Res. (2011) - PMID: 21908573
Prophylactic Transfer of BCR-ABL–, PR1-, and WT1-Reactive Donor T Cells after T cell–Depleted Allogeneic Hematopoietic Cell Transplantation in Patients with Chronic Myeloid Leukemia
Bornhäuser et al., Blood. (2011) - PMID: 21540460
Induction of Complete and Molecular Remissions in Acute Myeloid Leukemia by Wilms’ Tumor 1 Antigen-Targeted Dendritic Cell Vaccination
Tendeloo et al., PNAS (2010) - PMID: 20631300
Antigen-Specific Cytotoxic T Lymphocytes can Target Chemoresistant Side-Population Tumor Cells in Hodgkin’s Lymphoma
Shafer et al., Leuk Lymphoma. (2010) - PMID: 20367572
High-Avidity Cytotoxic-T-lymphocytes Specific for a New Preferentially Expressed antigen of Melanoma (PRAME)-Derived Peptide can Target Leukemic- and Leukemic-precursor Cells
Quintarelli et al., Blood (2010) - PMID: 21278353
MMP11: A Novel Target Antigen for Cancer Immunotherapy
Peruzzi et al., Clin Cancer Res (2009) - PMID: 19509157
Induction of Wilms' Tumor Protein (WT1)-Specific Antitumor Immunity Using a truncated WT1-Expressing Adenovirus Vaccine
Osada et al., Clin. Cancer Res. (2009) - PMID: 19351755
AtPTR1 and AtPTR5 Transport Sipeptides in Planta
Komarova et al., Plant Physiology Preview (2008) - PMID: 18753286
The Wilms' Tumor Antigen is a Novel Target for Human CD4 Regulatory T Cells: Implications for Immunotherapy
Lehe et al., Cancer Res. (2008) - PMID: 18676860
Three-Dimensional MR Mapping of Angiogenesis with 5 1(3)-targeted Theranostic Nanoparticles in the MDA-MB-435 Xenograft Mouse Model
Schmieder et al., The FASEB Journal (2008) - PMID: 18697838
Complete Responses of Relapsed Lymphoma Following Genetic Modification of Tumor-Antigen Presenting Cells and T-lymphocyte Transfer
Bollard et al., Blood (2007) - PMID: 17609424
An MVA Vaccine Overcomes Tolerance to Human p53 in Mice and Humans
Song et al., Cancer Immunol Immunother (2007) - PMID: 17219151

PepMix™ Peptide Pools - Tumor Associated Antigens